Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

NKTR-118

 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

naloxegol

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
The role of naloxegol in the management of opioid-induced bowel dysfunction
Opioid-induced constipation (OIC) and other gastrointestinal (GI) symptoms of opioid-induced bowel dysfunction (OIBD… Expand
  • figure 1
  • table 1
  • table 3
2015
2015
Safety, tolerability, pharmacokinetics, and pharmacodynamic effects of naloxegol at peripheral and central nervous system receptors in healthy male subjects: A single ascending‐dose study
This randomized, double‐blind, placebo‐controlled, ascending‐dose, crossover study evaluated single oral doses of naloxegol (NKTR… Expand
2015
2015
Safety, tolerability, and pharmacokinetics of multiple ascending doses of naloxegol
Opioid‐induced constipation (OIC) is the most common and often a treatment‐limiting adverse event (AE) of opioid therapy for… Expand
Highly Cited
2013
Highly Cited
2013
A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation
Summary Oral naloxegol was well tolerated and increased the frequency of spontaneous bowel movements in patients with opioid… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
2013
2013
New treatment possibilities for opioid-induced bowel dysfunction
The article by Webster et al. focused on the use of naloxegol in opioid-induced constipation (OIC) is important, as both OIC and… Expand
2010
2010
28th Annual JPMorgan Healthcare Conference--Exelixis and Nektar Therapeutics.
The JPMorgan Healthcare Conference, held in San Francisco, included presentations by various pharmaceutical companies summarizing… Expand
2009
2009
NKTR-118 Significantly Reverses Opioid-Induced Constipation
NKTR-118, a novel PEGylated naloxol conjugate, is an oral, once daily investigational agent in development for treatment of… Expand
  • figure 1
2009
2009
Efficacy, Safety and Pharmacokinetics of Oral NKTR-118 in Patients with Opioid-Induced Constipation: Results of a Randomized, Double-blind, Placebo-controlled Phase 2 Study: 466
 
2009
2009
AstraZeneca Inks Deal with Nektar
AstraZeneca has signed a licensing deal with Nektar Therapeutics to develop and market the latter’s two drugs, NKTR-118 and NKTR… Expand
2008
2008
(210) Results from a phase I, double-blind, randomized, placebo-controlled, multiple-dose study evaluating the safety, tolerability, and pharmacokinetics of oral doses of NKTR-118
 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE